KORU Medical Systems Joins Subcutaneous Drug Development & Delivery Consortium

KORU Medical Systems, Inc. (NASDAQ: KRMD) (“KORU Medical”), a leading medical technology company focused on the development of innovative and easy-to-use home infusion solutions, today announced its membership in the Subcutaneous (SC) Drug Development & Delivery Consortium (the “Consortium”), making it one of the first device companies to be added to the Consortium.

“The Consortium creates an important forum to identify and address key challenges and opportunities across the SC field,” said Linda Tharby, KORU Medical’s President and CEO. “Key industry experts can collaborate on issues at the clinical, regulatory, and commercial level and work towards advancing the SC market and creating the best outcomes for patients. I am excited for KORU Medical’s membership as one of the first device companies and look forward to advancing SC drug delivery.”

The Consortium was convened in 2018 as a community of well-recognized industry experts with decades of experience in the pharmaceutical drug delivery, device development, and commercialization space. The Consortium was built upon a strong desire for clear and transparent evidence-based communication of existing SC technologies and information. The Consortium’s mission is to identify current and future unmet medical needs within a dynamic SC drug delivery and development environment to transform patient care and improve patient outcomes. As a member, KORU Medical will contribute to advancing understanding of patient preference for SC therapy and the clinical trial strategy and technology for high-volume SC drugs. KORU Medical was one of the first companies to develop technology for SC biologics with volumes above 5mL, and its Freedom System is used by over 25,000 patients today to receive SC therapy. KORU Medical is established as the market leader in above 10mL and will bring this deep expertise in patient experience and subcutaneous injection technology to the Consortium.

About KORU Medical KORU Medical develops, manufactures, and commercializes innovative and easy-to-use specialty infusion solutions that improve quality of life for patients around the world. The FREEDOM Syringe Infusion System (the “Freedom System”) currently includes the FREEDOM60® and FreedomEdge® Syringe Infusion Drivers, Precision Flow Rate Tubing™ and HIgH-Flo Subcutaneous Safety Needle Sets™. These devices are used for infusions administered in the home and alternate care settings. For more information, please visit www.korumedical.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20221005005323/en/

Investor Contact: Greg Chodaczek 347-620-7010 [e-mail]